Efficacy and Safety of PSCK9 Inhibitors on Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Autor: Jiajing Zhao, Xinyu Tong, Jian Peng, Chuxin Lyu, Shu Lu

Publikováno v: Reviews in Cardiovascular Medicine, Vol 25, Iss 3, p 94 (2024)

Background: PCSK9 MaB (Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor) may reduce the occurrence of major adverse cardiovascular events (MACEs) in patients diagnosed with acute coronary syndrome (ACS). In this meta-analysis, we conducted a t

Externí odkaz: https://doaj.org/article/f97da2efed8646f5881068616dc2344e

Management of hyperlipidaemia following acute coronary syndrome: a retrospective audit.

Autor: Salim HY; Cardiology Specialist Registrar Worcester Royal Hospital, Charles Hastings Way, Worcester, WR5 1DD., Lwin K; Cardiology Specialist Registrar Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent, ST4 6QG., Khoo C; Consultant Cardiologist Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent, ST4 6QG., Wilson D; Consultant Cardiologist Worcester Royal Hospital, Charles Hastings Way, Worcester, WR5 1DD.

Publikováno v: The British journal of cardiology [Br J Cardiol] 2021 Apr 22; Vol. 28 (2), pp. 17. Date of Electronic Publication: 2021 Apr 22 (Print Publication: 2021).